ʻO kēia ka ʻāpono lāʻau 9th FDA i kākoʻo ʻia e Stand Up To Cancer noiʻi.
ʻO ka FDA i kēia manawa ua ʻae ʻia ka lāʻau lapaʻau immunotherapy pembrolizumab ma ke ʻano he lālani mua no nā maʻi me kekahi ʻano o maʻi ʻaʻai maʻi maʻi holomua. ʻO kēia ka ʻāpono 9th FDA i kākoʻo ʻia e Stand Up To Cancer® (SU2C) noiʻi.
Ua ʻike hou ʻia nā mea maʻi kiʻekiʻe-kiʻekiʻe a metastatic microsatellite instability-high (MSI-H) or mismatch hoʻoponopono hemahema (dMMR) colorectal cancer ma mua ua kauoha ʻia iā pembrolizumab wale nō ma hope o ka luhi ʻana i nā maʻamau chemotherapy maʻamau.
Ua ʻae ʻo FDA i ka pembrolizumab, i ʻike ʻia ma lalo o ka inoa inoa keytruda, me he lālani lālani mua no metastatic MSI-H — dMMR maʻi ʻaʻai kala i hoʻokumu ʻia ma nā hopena mua mai kahi hoʻokolohua hoʻokolohua pae III, i uku hapa ʻia e kahi haʻawina SU2C.
"Ke hoʻohālikelike ʻia i ka lapaʻau kuʻuna, ʻoi aku ka kiʻekiʻe o pembrolizumab me nā hopena ʻē aʻe no MSI-H — dMMR colorectal nā mea maʻi," i ʻōlelo ʻia ʻo Luis A. Diaz, MD, ke poʻo o ka mahele o Solid Tumor Oncology ma Memorial Sloan Kettering Cancer Center a me ke alakaʻi o ka Kime Moemoeā SU2C Colorectal Cancer, ka mea i alakaʻi i ka noiʻi. "Aia kekahi mau maʻi ʻaʻai paʻa paʻa ʻē aʻe i nā mākua a me nā keiki i loaʻa i kēia mau kīnā o MSI-H — dMMR, no laila he hopena paha kā kā mākou noiʻi no nā ʻano maʻi ʻaʻai ʻē aʻe."
Ma kahi o 4-5% o nā tumors cancer cancer he MSI-H — dMMR biomarkers, i hopena ʻia mai ka hiki ʻole o nā hunaola e hoʻoponopono hou i nā hewa i hana ʻia i ka wā o ke kaʻina o ka cellular a hiki ke alakaʻi i ka ulu nui ʻana o ka tumora.
ʻO ka noiʻi e pili ana iā 307 MSI-H — dMMR maʻi maʻi ʻaʻai kala i nā ʻāina he 23 i mālama ʻia me pembrolizumab a i ʻole chemotherapy maʻamau. Pahuhopu ʻo Pembrolizumab a palaka i kahi protein i kapa ʻia ʻo PD-1 i hiki ke pale aku i nā hunaola pale i kapa ʻia nā pūnaewele T mai ka hoʻopau maikaʻi ʻana i nā hunaola maʻi ʻaʻai.
Ua ʻike ʻo Kauka Diaz a me kāna hui i ka ʻike ʻole o ka maʻi maʻi MSI-H — dMMR i loaʻa me ka pembrolizumab i pāhola ʻia no 16.5 mau makahiki, ua hoʻohālikelike ʻia me nā mea maʻi i mālama ʻia me nā chemotherapy maʻamau i ʻike e ulu ana ko lākou tumors ma hope o ka median 8.2 mahina. ʻO nā mea maʻi e loaʻa ana i ka chemotherapy maʻamau ka hopena ʻoi aku ka maikaʻi ma mua o nā maʻi e loaʻa ana i ka pembrolizumab. Nā hopena hoʻopaʻa haʻawina piha ua paʻiʻia i ka New England Journal of Medicine ma Kekemapa 2, 2020.
"Ua kōkua nui ke kime ʻo Dream Colorectal Cancer Dream i kahi koho hoʻomaikaʻi hou aʻe no MSI-H — dMMR colorectal maʻi," i ʻōlelo ʻia ʻo Nobel laureate Phillip A. Sharp, PhD, ka luna o Stand Up To Cancer's Scientific Advisory Committee a he Kumu Kumu Kula ma ke Keʻena ʻo David H. Koch no ka Research Integrative Cancer Research ma Massachusetts Institute of Technology. "He laʻana maikaʻi loa kēia no ka hopena o ka Stand Up To Cancer i kahi noiʻi pololei i ka ola o nā mea maʻi maʻi maʻi."
ʻO ka maʻi ʻaʻai Colorectal ka ʻo ka lua o nā kumu maʻamau o ka make ʻana o ka maʻi ʻaʻai i waena o nā kāne a me nā wahine ʻAmelika i hui pū ʻia a kokoke NāʻAmelikaʻo 148,000 e loaʻa kahi hōʻoia hou o ke kolone a i ʻole ka maʻi ʻaʻai pololei i 2020. ʻOiai ua hōʻole nui ka make ʻana o ka maʻi ʻaʻai maʻi colorectal ma muli o ka hoʻonui ʻana o ka kānana a me nā hoʻomaikaʻi ʻana i ka lapaʻau. 1 o 3 mākua makahiki he 50 a ʻoi paha mai kiʻi i ka kānana i hōʻike ʻia. ʻO nā hihia hou o ka maʻi ʻaʻai kala ke kū nei i kahi ulu ulu i waena o nā poʻe ʻōpio a me nā makahiki waena i ka US, me ka helu o nā hihia o ka maʻi ʻaʻai kala i ka poʻe ma lalo o 50 e manaʻo e ʻaneʻane pālua ma 2030.
Ke hoʻomau nei ka maʻi kanesa colorectal i ka hopena maikaʻi ʻole o ka poʻe o ke kala
(Loaʻa i nā poʻe ʻeleʻele nā helu kiʻekiʻe o ka maʻi ʻaʻai kala o nā lāhui a lāhui paha i ka US), nā hoʻomaikaʻi ʻana i ka kānana ʻana a me nā kikoʻī hou a me nā hana e pono ai nā maʻi āpau. Ua hoʻolaha ʻo SU2C i kahi Initiative Health Equity In Ianative i Ianuali 2020. Pono ka papahana i nā hui e hiki mai ana e ʻimi ana i ke kālā ʻo Stand Up To Cancer e ʻōlelo i ka hoʻopaʻa ʻana a me ka mālama ʻana i nā mea maʻi mai nā lāhui like ʻole a me nā lāhui āpau a me nā kaiāulu i hoʻokau ʻia e hoʻomaikaʻi i ke komo like ʻana i nā hoʻokolohua maʻi maʻi maʻi maʻi. Hoʻokomo pū ʻia ka hoʻolālā i ka laulima ʻana me nā hui hoʻolaha a me nā ʻoihana a me nā mea kākoʻo ʻoihana e neʻe i ka noiʻi a me ka lehulehu i mua.
Mālama ʻia ka kime moe SU2C Colorectal Cancer Dream e Stand Up To Cancer's science hoa, ka Ka HuiʻAmelika no ka Hoʻoponopono Pākaʻi.
Kū i ka maʻi ʻaʻai
ʻO Mirabai Vogt-James
310-739-5576
André, T., ¶ AL. (2020) Pembrolizumab i loko o Microsatelit-Instability – ʻO ke kanulau maʻi kolokolo kiʻekiʻe. ʻO ka nūpepaʻo New England Journal of Medicine. doi.org/10.1056/NEJMoa2017699.
No nā kikoʻī hou aʻe hiki iā ʻoe ke kelepona iā mākou ma mozo@mozocare.com a kāhea paha + 91-8826883200